By Fineline Cube 
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase III ODYSSEY-HCM trial for its cardiac myosin inhibitor Camzyos (mavacamten). The study failed to meet its dual primary endpoints of improving the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS) and peak oxygen consumption (pVO₂) compared to placebo over 48 weeks.
Study Details and Outcomes
The ODYSSEY-HCM trial, the largest and longest-duration study conducted to date in patients with non-obstructive hypertrophic cardiomyopathy (nHCM), aimed to evaluate whether Camzyos could replicate the clinical benefits observed in obstructive HCM (oHCM). However, the results indicate that nHCM and oHCM are distinct diseases, with Camzyos showing limited efficacy in the non-obstructive form.
Camzyos’ Proven Efficacy in oHCM
Camzyos has demonstrated significant improvements in quality of life and functional capacity in patients with obstructive HCM through extensive clinical trials and real-world data. The drug works by reducing cardiac myosin activity, thereby improving heart function in patients with oHCM.
Implications and Future Directions
The ODYSSEY-HCM results highlight the need for novel therapeutic approaches tailored to non-obstructive HCM. BMS emphasized that the distinct pathophysiology of nHCM requires different treatment strategies, and the company remains committed to advancing research in this area to address unmet patient needs.-Fineline Info & Tech